+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

Bispecific Antibodies - Global Strategic Business Report - Product Thumbnail Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • November 2025
  • 104 Pages
  • Global
From
Immunotoxins - Global Strategic Business Report - Product Thumbnail Image

Immunotoxins - Global Strategic Business Report

  • Report
  • November 2025
  • 377 Pages
  • Global
From
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 198 Pages
  • Global
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • November 2025
  • 132 Pages
  • Global
From
From
Combination Antibody Therapy - Global Strategic Business Report - Product Thumbnail Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • November 2025
  • 196 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 193 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • November 2025
  • 224 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 193 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 277 Pages
  • Global
From
Cancer Gene Therapy Market - Global Forecast 2025-2032 - Product Thumbnail Image

Cancer Gene Therapy Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 199 Pages
  • Global
From
Nanotechnology in Cancer Treatment Market Report 2025 - Product Thumbnail Image

Nanotechnology in Cancer Treatment Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more